Controlled document PF-007A
PLEXUS SOLARIS Phase 1 Master Formula
Record identification
- Document ID
- PF-007A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-007A
PRODUCT FORMULA CARD
SIRIAM PLEXUS SOLARIS DUO – PHASE 1 (RELEASE)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-PS-001 |
| MF-007 |
| PF-007A |
| PLEXUS SOLARIS DUO – Phase 1 |
| T5–T9 |
| Orthosympathetic Release |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
The magistral fiche defines Phase 1 as orthosympathetic unloading with epigastric fascial release.
| Description |
|---|
| Neurodermal modulation of the solar plexus |
| T5–T9 |
| Orthosympathetic unloading and fascial release |
| Phase 1 – Release |
| Topical Magistral Cream |
2. MASTER FORMULA
Ingredient quantities are taken directly from the uploaded Phase 1 magistral fiche, with the agreed SQMS standardisation for Vitamin E and Silicea.
| Code |
|---|
| Official Ingredient |
| Supplier |
| Master Qty |
| Unit |
| Phase |
| PC-001 |
| Lanette Cream FNA |
| Fagron |
| 65.00 |
| g |
| B |
| PC-002 |
| Aqua Purificata |
| Fagron |
| 18.00 |
| g |
| W |
| SC-001 |
| Magnesium Chloride |
| Fagron |
| 4.00 |
| g |
| W |
| SC-002 |
| MSM |
| — |
| 2.50 |
| g |
| W |
| SC-003 |
| D-Panthenol (Natural Heroes) |
| Natural Heroes |
| 0.50 |
| g |
| W |
| SC-004 |
| Vitamin E Full Spectrum |
| Natural Heroes |
| 0.50 |
| g |
| L |
| BE-011 |
| Frankincense CO₂ (Boswellia serrata) |
| — |
| 0.25 |
| g |
| L |
| AC-006 |
| α-Bisabolol |
| — |
| 0.50 |
| g |
| L |
| BE-004 |
| Copaiba Oil |
| Aroma-Zone |
| 0.50 |
| g |
| L |
| HC-002 |
| Chelidonium majus D4 |
| — |
| 0.50 |
| mL |
| C |
| HC-004 |
| Carbo vegetabilis D6 |
| — |
| 0.50 |
| mL |
| C |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| — |
| 1.00 |
| mL |
| C |
| BE-012 |
| Commiphora myrrha Tincture |
| — |
| 0.50 |
| mL |
| C |
| AC-007 |
| Syn®-Ake Peptide Complex |
| — |
| 0.50 |
| mL |
| C |
| CL-001 |
| Sea Buckthorn CO₂ Colour |
| — |
| 1 |
| drop |
| C |
| PR-001 |
| Cosgard 221 |
| Aromantic |
| 0.70 |
| g |
| C |
3. MANUFACTURING WORKFLOW
Step
1
2
3
4
5
6
7
8
9
10
11
This follows the standard 10-step Lanette protocol described in the source fiche.
| Action |
|---|
| ✓ |
| Verify raw materials |
| □ |
| Prepare water phase |
| □ |
| Prepare lipid dispersion |
| □ |
| Emulsification |
| □ |
| Add Silicea Gel |
| □ |
| Cool below 35°C |
| □ |
| Incorporate thermolabile ingredients |
| □ |
| Final homogenisation |
| □ |
| Quality Control |
| □ |
| Fill airless dispensers |
| □ |
| Batch Release |
| □ |
4. QUALITY CONTROL
Parameter
Appearance
Colour
Odour
Homogeneity
pH
Viscosity
Packaging
Net Weight
| Target |
|---|
| Result |
| Standard |
| Standard |
| Standard |
| Pass |
| 5.2–5.5 |
| Airless compatible |
| Pass |
| Pass |
5. BATCH RELEASE
Field
Batch Number
Production Date
Yield
Prepared by
Checked by
Released by
| Value |
|---|
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Primary Target Zone
Frequency
Treatment Phase
Clinical application zones follow the magistral protocol.
| Value |
|---|
| T5–T9 |
| Paravertebral T5–T9 |
| Lateral costal arches |
| Epigastric (Solar Plexus) |
| 1–2× daily |
| Weeks 1–2 |
Related documents
Platform modules